Y-Intercept (HK)’s BridgeBio Pharma BBIO Stock Holding History

Y-Intercept (HK)’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8M	Buy	+107,419	New	+$7.52M	0.16%	140
2026 Q1	–	Sell	-54,110	Closed	-$4.14M	–	1556
2025 Q4	$4.14M	Buy	54,110 +40,179	+288%	+$2.64M	0.09%	293
2025 Q3	$724K	Sell	13,931 -197,101	-93%	-$9.61M	0.02%	1115
2025 Q2	$9.11M	Buy	+211,032	New	+$7.68M	0.22%	84
2025 Q1	–	Sell	-25,980	Closed	-$713K	–	1202
2024 Q4	$713K	Buy	25,980 +12,701	+96%	+$328K	0.05%	571
2024 Q3	$338K	Buy	+13,279	New	+$349K	0.02%	963
2024 Q1	–	Sell	-26,192	Closed	-$1.06M	–	1371
2023 Q4	$1.06M	Buy	26,192 +11,988	+84%	+$360K	0.1%	297
2023 Q3	$375K	Buy	+14,204	New	+$403K	0.04%	674
2022 Q4	–	Sell	-20,217	Closed	-$201K	–	1001
2022 Q3	$201K	Buy	+20,217	New	+$210K	0.02%	823

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Y-Intercept (HK)'s BBIO Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 107,419 shares worth $8M. The stake represents 0.16% of the portfolio and ranks #140 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in BBIO as recently as Q4 2025.

Y-Intercept (HK) first reported a position in BBIO in Q3 2022 and has held it in 9 quarters since. The position peaked at $9.11M in Q2 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Y-Intercept (HK) held 107,419 shares of BridgeBio Pharma worth $8M as of Q2 2026.
BridgeBio Pharma was a new Y-Intercept (HK) position in Q2 2026.
BridgeBio Pharma made up 0.16% of Y-Intercept (HK)'s portfolio in Q2 2026, its #140 holding.
Y-Intercept (HK) first reported a position in BridgeBio Pharma in Q3 2022 and has held it in 9 quarters since.
Y-Intercept (HK)'s BridgeBio Pharma position peaked at $9.11M in Q2 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.